Article

One For Choosing Wisely in Breast Cancer

A study presented at the San Antonio Breast Cancer Symposium showed that Herceptin may not complement chemotherapy in breast tumors with a high level of immune infiltration.

HER2-positive breast cancers with a high level of immune cell infiltration might not benefit from the addition of trastuzumab (Herceptin) to chemotherapy, a trial analysis suggested.

The 10% of patients with stromal tumor-infiltrating lymphocyte-predominant breast cancer in the Alliance N9831 trial showed similar recurrence-free survival whether they received chemotherapy alone or with trastuzumab (10-year rate 90.9% versus 80.0%, P = .21), Edith A. Perez, MD, of the Mayo Clinic in Jacksonville, Florida, and colleagues found.

The rest showed, as expected, significantly better recurrence-free survival with addition of trastuzumab (10-year rate 79.6% vs 64.3%, hazard ratio .49, P = .0003), they reported at the San Antonio Breast Cancer Symposium.

Link to the complete report: http://bit.ly/1GjDd6y

Source: Medpage Today

Related Videos
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Neal D. Shore, MD
Amit Singal, MD, UT Southwestern Medical Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo